
==== Front
J Neurooncol
J Neurooncol
Journal of Neuro-Oncology
0167-594X
1573-7373
Springer US New York

38427131
4613
10.1007/s11060-024-04613-6
Case Study
Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors
Rogers James L. 1
Wall Thomas 1
Acquaye-Mallory Alvina A. 1
Boris Lisa 1
Kim Yeonju 126
Aldape Kenneth 2
Quezado Martha M. 2
Butman John A. 3
Smirniotopoulos James G. 1
Chaudhry Huma 4
Tsien Christina I. 15
Chittiboina Prashant 6
Zaghloul Kareem 6
Aboud Orwa 7
Avgeropoulos Nicholas G. 825
Burton Eric C. 1
Cachia David M. 9
Dixit Karan S. 10
Drappatz Jan 11
Dunbar Erin M. 12
Forsyth Peter 13
Komlodi-Pasztor Edina 114
Mandel Jacob 15
Ozer Byram H. 1
Lee Eudocia Q. 16
Ranjan Surabhi 17
Lukas Rimas V. 10
Raygada Margarita 18
Salacz Michael E. 19
Smith-Cohn Matthew A. 120
Snyder James 21
Soldatos Ariane 22
Theeler Brett J. 23
Widemann Brigitte C. 24
Camphausen Kevin A. 4
Heiss John D. 6
Armstrong Terri S. 1
Gilbert Mark R. 1
http://orcid.org/0000-0002-0860-3805
Penas-Prado Marta marta.penas-prado@nih.gov

1
1 grid.48336.3a 0000 0004 1936 8075 Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9030 Old Georgetown Rd, Bethesda, MD 20892 USA
2 grid.48336.3a 0000 0004 1936 8075 Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Dr, Bethesda, MD 20892 USA
3 https://ror.org/01cwqze88 grid.94365.3d 0000 0001 2297 5165 Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, 10 Center Dr, Bethesda, MD 20892 USA
4 grid.48336.3a 0000 0004 1936 8075 Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Dr, Bethesda, MD 20892 USA
5 grid.430179.8 0000 0004 0432 1012 Proton Therapy Center, Sibley Memorial Hospital, Johns Hopkins Medicine, 5255 Loughboro Rd NW, Washington, DC 20016 USA
6 grid.416870.c 0000 0001 2177 357X Surgical Neurology Branch,, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Dr, Bethesda, MD 20892 USA
7 https://ror.org/02kcc1z29 0000 0004 0394 5528 Department of Neurology and Neurological Surgery, UC Davis Comprehensive Cancer Center, 4860 Y Street, Sacramento, CA 95817 USA
8 grid.416912.9 0000 0004 0447 7316 Brain and Spine Tumor Program, Orlando Health Cancer Institute, 1400 S. Orange Ave, Orlando, FL 32806 USA
9 https://ror.org/04ydmy275 grid.266685.9 0000 0004 0386 3207 Department of Hematology/Oncology, University of Massachusetts, 55 Lake Ave, Worcester, MA 01655 USA
10 https://ror.org/000e0be47 grid.16753.36 0000 0001 2299 3507 Lou and Jean Malnati Brain Tumor Institute, Northwestern University Feinberg School of Medicine, 675 N St Clair St, Chicago, IL 60611 USA
11 grid.412689.0 0000 0001 0650 7433 Department of Neurology, University of Pittsburgh Medical Center, 5115 Centre Ave, Pittsburgh, PA 15232 USA
12 https://ror.org/0008s4w86 grid.414991.0 0000 0000 8868 0557 Piedmont Brain Tumor Center, Piedmont Atlanta Hospital, Atlanta, GA 2001 Peachtree St30309 USA
13 https://ror.org/01xf75524 grid.468198.a 0000 0000 9891 5233 Department of Neuro-Oncology, Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, FL 33612 USA
14 https://ror.org/03ja1ak26 grid.411663.7 0000 0000 8937 0972 Department of Neurology, MedStar Georgetown University Hospital, 3800 Reservoir Road Washington, Washington DC, 20007 USA
15 https://ror.org/02pttbw34 grid.39382.33 0000 0001 2160 926X Department of Neurology, Baylor College of Medicine, 7200 Cambridge St, Houston, TX 77030 USA
16 grid.65499.37 0000 0001 2106 9910 Center for Neuro-Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215 USA
17 https://ror.org/0155k7414 grid.418628.1 0000 0004 0481 997X Department of Neurology, Cleveland Clinic Florida, Weston Hospital, 2950 Cleveland Clinic Boulevard, Weston, FL 33331 US
18 grid.420089.7 0000 0000 9635 8082 Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, 1 Center Dr, Bethesda, MD 20892 USA
19 https://ror.org/056nm0533 grid.421534.5 0000 0004 0524 8072 Department of Hematology and Medical Oncology, MD Anderson Cancer Center at Cooper, Cooper University Health Care, Two Cooper Plaza, Camden, NJ 08103 USA
20 grid.429736.d Benefis Sletten Cancer Institute, 1117 29Th St. S, Great Falls, MT 59405 USA
21 grid.446722.1 0000 0004 0635 5208 Hermelin Brain Tumor Center, Henry Ford Cancer Institute, 2800 W Grand Blvd, Detroit, MI 48202 USA
22 grid.94365.3d 0000 0001 2297 5165 National Institute of Neurological Disorders and Stroke,, National Institutes of Health, 10 Center Dr, Bethesda, MD 20892 USA
23 grid.265436.0 0000 0001 0421 5525 School of Medicine, Uniformed Services University, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA
24 grid.48336.3a 0000 0004 1936 8075 Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Dr, Bethesda, MD 20892 USA
25 grid.523802.e Global Medical Affairs, Novocure GmbH, D4 Pk. 6, 6039 Root, Switzerland
26 https://ror.org/01070mq45 grid.254444.7 0000 0001 1456 7807 Wayne State University School of Medicine, 540 E Canfield St, Detroit, MI 48201 USA
1 3 2024
1 3 2024
2024
167 2 349359
29 12 2023
17 2 2024
© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2024, corrected publication 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Purpose

Multidisciplinary tumor boards (MTBs) integrate clinical, molecular, and radiological information and facilitate coordination of neuro-oncology care. During the COVID-19 pandemic, our MTB transitioned to a virtual and multi-institutional format. We hypothesized that this expansion would allow expert review of challenging neuro-oncology cases and contribute to the care of patients with limited access to specialized centers.

Methods

We retrospectively reviewed records from virtual MTBs held between 04/2020–03/2021. Data collected included measures of potential clinical impact, including referrals to observational or therapeutic studies, referrals for specialized neuropathology analysis, and whether molecular findings led to a change in diagnosis and/or guided management suggestions.

Results

During 25 meetings, 32 presenters discussed 44 cases. Approximately half (n = 20; 48%) involved a rare central nervous system (CNS) tumor. In 21% (n = 9) the diagnosis was changed or refined based on molecular profiling obtained at the NIH and in 36% (n = 15) molecular findings guided management. Clinical trial suggestions were offered to 31% (n = 13), enrollment in the observational NCI Natural History Study to 21% (n = 9), neuropathology review and molecular testing at the NIH to 17% (n = 7), and all received management suggestions.

Conclusion

Virtual multi-institutional MTBs enable remote expert review of CNS tumors. We propose them as a strategy to facilitate expert opinions from specialized centers, especially for rare CNS tumors, helping mitigate geographic barriers to patient care and serving as a pre-screening tool for studies. Advanced molecular testing is key to obtaining a precise diagnosis, discovering potentially actionable targets, and guiding management.

Supplementary Information

The online version contains supplementary material available at 10.1007/s11060-024-04613-6.

Keywords

Collaborative practice
Multidisciplinary tumor boards
National Cancer Institute-Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT)
Rare CNS tumors
Barriers to healthcare access
This research was funded by the NCI Comprehensive Oncology Network for Evaluating Rare CNS Tumors (NCI-CONNECT), a program within the Rare Tumor Patient Engagement Network (RTPEN), an initiative supported by Cancer Moonshot℠ funds and managed at the National Institutes of Health, National Cancer Institute, Center for Cancer Research, Neuro-Oncology Branchissue-copyright-statement© Springer Science+Business Media, LLC, part of Springer Nature 2024
==== Body
pmcIntroduction

Multidisciplinary tumor boards (MTB) help coordinate [1–3] and deliver complex care to patients with central nervous system (CNS) tumors [4] and have been suggested as a quality metric by the American Academy of Neurology and Society for Neuro-Oncology [5]. Optimal care involves collaboration across specialties, including neuro-oncology, medical oncology, neuroradiology, neurosurgery, radiation oncology, neuropathology, and others. This diverse clinical expertise is often clustered in large academic centers, making MTBs mostly feasible within this environment. Virtual meetings provide a unique opportunity for participation of providers located at different institutions, facilitating the identification of unusual diagnoses and personalized management for patients who otherwise would have difficult in-person access to the expert care located in these tertiary or quaternary institutions.

Previous studies have explored the use of MTBs in breast [6], colorectal [7], esophageal [8], gynecological [9], head and neck [1], lung[10], upper-gastrointestinal [11], and urological [12] cancers, as well as in other mixed cancer cohorts [13, 14]. Their role in neuro-oncology has been explored in recent publications. In a US nationwide provider survey, Snyder et al. (2017) identified four benefits of neuro-oncology MTBs (coordination of care, direction for complicated cases, education, and communication of potential clinical trials) [4]. Khalafallah et al. (2020) quantified the utility of neuro-oncology MTBs reporting numerous diagnostic and treatment plan changes and shortened referral times [15]. Schäfer et al. (2021) administered a German nationwide provider survey, identifying that virtual neuro-oncology MTBs are feasible and acceptable [16]. Gaudino et al. (2022) described their experience holding neuro-oncology MTB meetings in Italy, noting the significance and limitations of incorporating imaging review by an expert neuroradiologist [17]. Lastly, a study by Ivanovic et al. at a tertiary academic center demonstrated a strong correlation between high MTB participation and low diagnostic error rates by neuroradiologists [18]. As suggested by these publications, MTBs are clinically impactful in neuro-oncology, benefiting both providers and patients.

However, while MTBs are common in specialized neuro-oncology centers, no study has yet analyzed their utility in 1) allowing virtual participation of multiple institutions, and 2) providing remote expert guidance for providers taking care of patients with rare CNS tumors, whose diagnosis and management are particularly challenging [19]. Few centers have the expertise to perform advanced molecular testing and/or develop tailored treatment plans for these uncommon tumors. At the National Cancer Institute (NCI), several authors of this manuscript participate in caring for patients with rare CNS tumors under the NCI’s Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT; https://ccr.cancer.gov/neuro-oncology-branch/connect), a program to advance the understanding of a pilot group of rare CNS cancers in adults, including atypical teratoid rhabdoid tumor (ATRT), choroid plexus tumors, histone mutated gliomas, ependymoma, gliomatosis cerebri, gliosarcoma and primary CNS sarcomas, medulloblastoma, high-grade meningioma, IDH mutated gliomas, parenchymal pineal region tumors, BRAF-altered tumors, embryonal tumors formerly known as primitive neuro-ectodermal tumors, and DNA methylation-defined emerging CNS tumors. In the US, these rare tumors have an estimated prevalence in the low hundreds up to < 14,000 individuals across all ages, and an incidence in adults ranging from a few tens to a little over a thousand new cases per year[20–25]. NCI-CONNECT facilitates referrals to a specialized quaternary center focused on clinical epigenetics and management of rare CNS tumors [26]. Specialized care can reduce the likelihood of misdiagnosis and treatment-related complications, resulting in more appropriate management and, ultimately, improved outcomes [27].

Review and discussion of cases among providers from different institutions can be accomplished remotely, facilitating referrals to tertiary and quaternary centers and circumventing typical geographic constraints and other barriers that limit obtaining second opinions from specialized centers [28]. In this study, we describe our experience of remotely reviewing neuro-oncology cases, with a primary focus on rare CNS tumors, during virtual MTBs hosted by the NCI Neuro-Oncology Branch and open to the participation of multiple institutions. While findings are reported in the context of the COVID-19 pandemic, we propose virtual multi-institutional tumor boards led by specialized centers as a strategy to optimize neuro-oncology clinical practice, especially for uncommon CNS tumors.

Materials and Methods

Overview of the Virtual MTB

At the National Institutes of Health (NIH), Neuro-Oncology MTBs were traditionally held in-person and focused on internal cases. In March 2020, due to the COVID-19 pandemic, the MTB was transitioned to a virtual format. This permitted expanding participation to multiple clinical teams from neighbor institutions and over 30 Brain Tumor Trials Collaborative (BTTC)/NCI-CONNECT network centers across the US, enabling the presentation of external cases. This virtual multi-institutional format continues at present.

Preparation for the Virtual MTB

Before each MTB, presenters complete a standardized portable document format (PDF) data capture form (see Supplementary Material 1), inquiring about date of initial diagnosis, reason for discussion at MTB, and de-identified brief patient narrative (e.g., age, gender, handedness, current Karnofsky Performance Status (KPS) score, relevant symptoms and exam findings, and treatment summary). This form is emailed to MTB attendees to allow them to review the basic case details before MTB.

During the Virtual MTB

Virtual CME-accredited neuro-oncology MTBs have been held since April 2020, 2–4 times per month, via the WebEx video teleconferencing platform (WebEx by Cisco, San Jose, California, US), vetted by the NIH Center for Information Technology to be secure for patient care discussions. Meetings are attended by a diverse group of clinicians, researchers, and trainees from the NIH and BTTC/NCI-CONNECT network and other external sites.

The presenter is asked to share a deidentified patient summary and display relevant imaging and pathology results including molecular data if already available. NIH neuroradiologists and neuropathologists comment on the data. NIH neuro-oncologists, neurosurgeons, radiation oncologists, a patient-reported outcomes expert, a genetic counselor, and other external clinicians, are invited to provide input on diagnosis and management strategies, including potential clinical trial options when applicable. MTBs are moderated to ensure adequate time and discussion for each case and summarize the suggestions for the presenter(s). Attendees are asked to keep all information confidential, and presenters are advised that the tumor board suggestions are meant to contribute, but not dictate, the final management of their cases.

After the Virtual MTB

A PDF document is emailed to the presenter with a summary of the discussion and suggestions, including available research protocols. Presenters are encouraged to bring their cases back for follow-up when appropriate. Frequently, presenters are offered to refer their patients for an in-person visit under the NCI Natural History Study (NCT02851706; PI: T. S. Armstrong) and/or submit a request for neuropathology consultation at the NIH, particularly if the diagnosis was unclear based on histopathological features and available molecular data. For such reviews, presenters are asked to ship tumor tissue to the NCI Laboratory of Pathology for testing, including use of a custom next-generation DNA and RNA sequencing gene panel and DNA methylation-based classifier [29]. For patients referred for an in person visit, the observational NCI Natural History Study enables tumor tissue testing and longitudinal clinical tracking of patients throughout their disease, seeking to understand epidemiologic risk factors and tumor molecular features, and using clinical outcomes assessments to monitor the impact of the disease and treatment on how patients feel and function. Patients with rare CNS tumors also receive evaluation by a genetic counselor and have access to the Coping, Advocacy, Relationships, Education, and Support (CARES) group program, which supports wellness and creates connections among rare CNS tumor patients.

Retrospective MTB Record Review

As of July 2023, a total of 154 cases have been presented (112 external, including 2 international, with presentations by 47 different external institutions). We retrospectively reviewed standardized PDF, medical, and email records from the first year of virtual MTBs (April 2020-March 2021). The following variables were extracted by J.L.R. and T.W., under the guidance of the senior author (M.P.P.): date of the presentation, presenter’s name and affiliation, patient’s age, pre-MTB diagnosis, timing along the disease trajectory (e.g., newly diagnosed, recurrent, other), tumor location, and presence of dissemination in the CNS or systemically (yes or no; locations).

Additionally, the suggestions offered during the presentation were collected, including: 1) in person participation in the NCI Natural History Study, 2) participation in a therapeutic clinical trial at the NIH and/or other institutions, 3) further neuropathology review and molecular testing at the NIH. Data collection also included: 1) if molecular profiling was performed by NIH (before or after MTB), 2) if molecular findings led to a change in diagnosis (new diagnosis or further sub-classification), and 3) if the molecular findings (obtained at the NIH or elsewhere) guided management suggestions (germline testing/genetic counseling, observation vs. treatment, or specific treatment options).

Statistical Analyses and Ethical Approval

All data were analyzed using Microsoft Excel, version 16.59 (Microsoft Corporation, Redmond, Washington, US). Due to the number of cases and the retrospective nature of the review, only descriptive statistics were obtained and reported.

The National Institutes of Health (NIH) Office of IRB Operations (IRBO) determined that the study did not require IRB review or approval. Patient consent was waived because only deidentified data were discussed and extracted.

Results

During 25 virtual meetings held between April 2020-March 2021, 32 providers from 18 institutions presented 44 cases (range: 1–4 cases/meeting). Of these cases, 12 (27%) were presented by an NIH clinician, 25 (57%) by an outside clinician, and 7 (16%) were mutual cases presented jointly by NIH and outside clinicians. Two out of these 44 cases (5%) were presented for their educational value and were not seeking discussion regarding diagnosis or management. Therefore, only 42 cases (with 1 case presented twice; 41 unique patients) were included for further analyses of MTB impact. Table 1 summarizes the patient’s age and the pre and post MTB diagnoses. Of these 41 unique patients, 13 had dissemination outside of the primary location (n = 6) and/or outside the CNS (n = 13). The median age was 40 years of age (range 15 to 73), with 20 (49%) being adolescents and young adults (AYA). At the time of MTB presentation, 36% cases (n = 15) were newly diagnosed, 38% (n = 16) had recurrence, and 26% (n = 11) were classified as “other,” indicating mainly lack of clarity between recurrence and treatment-related effects. Tumor types were 9 infiltrating gliomas, 8 ependymomas, 5 embryonal tumors, 4 circumscribed astrocytic gliomas, 3 glioneuronal tumors, 3 meningiomas, 3 mesenchymal, non-meningothelial tumors, 1 paraspinal nerve tumor, 1 sellar tumor, and 4 were non-classifiable or undiagnosed histology. Approximately half of the cases (n = 20, 48%) involved an NCI-CONNECT rare CNS tumor. At the time of presentation, 29% (n = 12) of patients were already enrolled on the NCI Natural History Study and 40% (n = 17) had already been reviewed by the NIH Laboratory of Pathology team (either as Natural History Study participants or as external consultations). Table 1 Pre and post tumor board diagnoses after incorporation of molecular data obtained at the NIH 

Patient age	Pre-tumor board diagnosis*	Post-tumor board change	
43	Astrocytoma, WHO Grade 2	Yes—Subclassification

(IDH mutant)

Change in grade from 2 to 3

	
22	Astrocytoma, WHO Grade 3#	No	
43	Glioblastoma, IDH mutant	No	
NC	Glioblastoma, IDH wild-type, MGMT methylated	No	
73	Glioblastoma, IDH wild-type	No	
46	High-grade astrocytoma with molecular features of Glioblastoma	No	
52	Infiltrating glioma, IDH wild-type	No	
66	Diffuse midline glioma&, H3K27M mutant	No	
36	Pilocytic astrocytoma with BRAF fusion	No	
66	Infiltrating glioma, IDH wild-type, BRAF fusion	Yes—Revised diagnosis

(Pilocytic astrocytoma)

	
27	Pleomorphic xanthoastrocytoma&, WHO Grade 3	No	
29	Ganglioglioma	No	
47	Diffuse leptomeningeal glioneuronal tumor	No	
51	Rosette-forming glioneuronal tumor, WHO Grade 1	No	
39	Ependymoma&, WHO Grade 3	No	
27	Supratentorial RELA-fusion ependymoma&	No	
67	Ependymoma&	Yes—Subclassification

(PF-B)

	
50	Ependymoma&, WHO Grade 3	Yes—Subclassification

(PF-B)

	
25	Ependymoma&, WHO Grade 3	Yes—Subclassification

(MYCN amplified ependymoma)

	
30	MYCN-amplified anaplastic ependymoma&	No	
47	Myxopapillary ependymoma&	No	
42	Myxopapillary ependymoma&	No	
47	Medulloblastoma&, SHH subgroup and pituitary mass (macroadenoma vs. metastatic medulloblastoma)	No	
48	Medulloblastoma&	Yes—Subclassification

(SHH subgroup)

	
40	Medulloblastoma&, SHH subgroup	No	
37	High-grade neuroendocrine tumor/Primitive neuroepithelial tumor&	Yes—Revised diagnosis

(Atypical teratoid/rhabdoid tumor, MYC subtype)

	
25	Atypical teratoid/rhabdoid tumor&	No	
61	Malignant melanocytic schwannian tumor	No	
40	Meningioma& (WHO grade 1 vs. grade 2)	Yes—Subclassification

(DNA Methylation show higher risk)

	
65	Meningioma&, WHO grade 1	No	
57	Meningioma&(WHO grade 1 vs. grade 2)	No	
30	Hemangioblastoma, WHO grade 1	No	
NC	High-grade pleomorphic spindle cell sarcoma3	No	
38	Myxoid mesenchymal tumor with EWSR1-ATF1 fusion	No	
21	Craniopharyngioma, adamantinomatous	No	
18	Infiltrating glioma; IDH1, BRAFV600E negative; H3K27me3 retained	No	
40	High-grade glioma with ependymal and sarcomatous differentiation	No	
35	CNS embryonal tumor with rhabdoid features&	Yes—Revised diagnosis

(High-grade neuro-epithelial tumor with MN1 alteration)

	
54	Undiagnosed

(brain lesions in patient with Hodgkin’s lymphoma)

	No	
15	Undiagnosed

(fibrous lesion vs. low grade sarcoma)

	No	
17	Undiagnosed

(inflammatory non-neoplastic entity)

	No	
*Tumors were presented and therefore classified before the release of the latest 2021 WHO Classification of Tumors of the Central Nervous System [35]. The current designation of Glioblastoma, IDH-mutant is Astrocytoma, IDH-mutant, WHO grade 4. Supratentorial RELA-fusion ependymoma is now Supratentorial ependymoma, ZFTA fusion-positive

#This case was presented to the tumor board twice

&NCI-CONNECT tumor type

Abbreviations: IDH, Isocitrate Dehydrogenase; LMD, leptomeningeal disease; MCYN, V-Myc Avian Myelocytomatosis Viral Oncogene Neuroblastoma Derived Homolog; MGMT, O6-Methylguanine-DNA Methyltransferase; N/A, Not Applicable; NCI-CONNECT, National Cancer Institute-Comprehensive Oncology Network Evaluating Rare CNS Tumors; NC, Not Collected; RELA, V-Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A; SHH, Sonic Hedgehog; WHO, World Health Organization

As displayed in Table 2, 31% of cases (n = 13) received a recommendation for participation in therapeutic clinical trials. Of these patients, 8 were potentially eligible for trials at the time of MTB presentation, including trials enrolling at the NIH (n = 5), an external institution (n = 1), or both NIH and an external institution (n = 2). Five additional patients were potentially eligible for NIH trials at the time of future disease progression. Table 2 Summary of tumor board suggestions

Tumor board suggestion or outcome	N	%	
Offered participation in observational NCI Natural History Study*	9	21.4	
Offered neuropathology review and molecular testing at NIH	7	16.7	
Offered participation in therapeutic trial now or if future progression/recurrence:	13	31.0	
Trial at NIH, now**	7	16.7	
Trial at external institution, now**	3	7.1	
Trial at NIH, if future progression/recurrence	5	11.9	
Cases where molecular findings# guided management:	15	35.7	
Germline testing/counseling recommended	3	7.1	
Observation vs. treatment recommended	3	7.1	
Specific treatment options recommended	11	26.2	
* NCT02851706

**Two patients received suggestions for trials both at NIH and an external site. Eight patients received trial suggestions for current clinical needs

#Molecular findings available at the time of tumor board presentation, obtained at the NIH or outside. More than one recommendation was given in one case (i.e., both germline testing/counseling and observation vs. treatment)

Abbreviations: NCI, National Cancer Institute; NIH, National Institutes of Health

Additionally, of the total 42 cases discussed, 21% (n = 9) were offered enrollment in the NCI Natural History Study, 17% (n = 7) were recommended neuropathology review at the NIH, including advanced molecular testing due to diagnostic uncertainty, and 100% (n = 42) received suggestions for further management.

In 52% of cases (n = 22) molecular profiling occurred at the NIH, either before or after MTB presentation. In 15 cases, molecular findings available during presentation (either obtained at the NIH or outside), guided MTB management suggestions in one or more of these areas: 1) observation versus treatment (n = 3); 2) specific treatment selection (n = 11); 3) recommendation to proceed with germline testing and/or genetic counseling (n = 3) (Table 2). Lastly, MTB discussions resulted in 9 (21.4%) cases having a diagnosis change (Table 1), including identification of an entirely new diagnosis (n = 3: from infiltrating glioma to pilocytic astrocytoma; from primitive neuroepithelial tumor to AT/RT; and from CNS embryonal tumor with rhabdoid features to astroblastoma, MN1-altered) or further subclassification (n = 6: identified molecular subgroup in 3 ependymomas and 1 medulloblastoma; 1 infiltrating astrocytoma classified as IDH-mutant and increased grade; and 1 meningioma classified as higher risk based on DNA methylation). Supplementary Table 1 provides a summary of all the cases for which molecular data obtained at the NIH and/ or elsewhere was important in guiding diagnosis or the suggestions of the MTB. This supplementary table includes the listing of the molecular aberrations, methods used, if diagnosis was changed or further classified, a summary of the suggestions provided by the MTB and evidence level.

Discussion

MTBs can optimize the delivery of complex cancer care [13]. We report our experience of organizing a regular virtual MTB with participants from multiple institutions for discussion of complex neuro-oncology cases including rare CNS tumors. The results of a retrospective record review suggest that the virtual MTB is an effective forum for discussions of molecular, radiological, and clinical information for personalized diagnoses and patient management suggestions, particularly for patients with rare CNS tumors for which specialized care can be difficult to access.

Opening the meetings to outside participation fostered collaboration among providers from multiple institutions throughout the US, as illustrated by the mutual cases presented jointly by NIH and outside clinicians. Additionally, similar to the tumor board conferences outlined by Snyder et al. (2017) [4], our virtual MTBs involved members of diverse subspecialties. Engaging a multidisciplinary audience from multiple institutions enabled different specialists to inform management, a crucial benefit of team-based virtual tumor board meetings [30].

Unfortunately, there are many barriers to specialized care and enrollment in therapeutic clinical trials in neuro-oncology. As Lee et al. (2019) outlined, physician-related logistical barriers may impede referral to clinical trials, among multiple other factors [31]. In our virtual MTB, almost 1/3 of presented cases received therapeutic clinical trial suggestions. Additionally, 21% (n = 9) were offered enrollment in the observational NCI Natural History Study, providing an opportunity to collect prospective data in rare CNS tumors. As Rogers et al. (2020) noted in their survey of the Society for Neuro-Oncology members, the most commonly reported provider-referral barrier was finding trials in the patient’s geographic area [32]. In our experience, virtual MTB meetings with colleagues from across the US aided in identifying appropriate therapeutic or observational studies in which patients could realistically enroll.

In recent years, objective and biologically-driven methods for classification of CNS tumors have been increasingly adopted [33]. The cIMPACT-NOW group (Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy) pushed for an updated classification considering the rapid progress in molecular insights into these neoplasms [34]. Notably, the new fifth edition of the WHO Classification, published in 2021, advances the role of molecular testing and emphasizes the importance of integrated diagnoses [35]. In the new “molecular era” of neuro-oncology, targeted next-generation sequencing [36] and DNA methylation profiling, particularly the DKFZ/Heidelberg CNS tumor classifier [29, 37], have emerged as important precision diagnostic tools [33] that directly impact patient care [38]. In diagnostically complex neuro-oncology cases (especially those involving rare CNS tumors), methylation profiling has been particularly diagnostically useful [39].

Neuropathologic review by the NIH and available molecular findings discussed during MTBs guided management, including observation versus treatment, specific treatment selection, and recommendation for germline testing and/or genetic counseling. Therefore, molecular findings were leveraged to achieve accurate, personalized diagnoses and develop individualized patient management. Based on our experience, molecular profiling is particularly valuable for any cases with equivocal or insufficient histopathological features for proper classification into a defined WHO category or subcategory. For example, astroblastomas-MN1 altered, molecular subtypes of ependymoma and medulloblastoma subgroups require this advanced testing.

All cases presented at MTB received suggestions for management, with most providers reporting, via quality improvement surveys (not reported here), that the suggestions impacted their patient management. Virtual MTB discussions also resulted in diagnosis changes for 21% of cases, including identification of entirely new diagnoses and further subclassification. This finding highlights the importance of referring patients to highly specialized neuro-oncology centers, which leverage advanced molecular testing as a complement to traditional histology, have rich experience in imaging interpretation [40], and incorporate a robust basic, translational, and clinical research program [41].

The virtual MTB was particularly impactful for those with ependymomas and other rare CNS tumors that are infrequently seen by most clinicians, even in academic centers. Approximately half of the presented cases involved the diagnosis and management of an NCI-CONNECT rare CNS tumor and the median age was young. While many of the rare tumors presented at the MTB still lack well-defined standards of care [26], the NCI-CONNECT program is fostering progress by publishing guidelines [22] and hosting expert workshops [22, 23, 25, 27]. Therefore, our virtual MTB offered providers guidance and possibly offered patients reassurance that their case was being reviewed by a diverse group of specialists with the knowledge and tools needed to provide informed treatment suggestions, a critical benefit worth exploring in future studies [42].

This study has several limitations. The retrospective record review increased the potential for missing data. The early morning timing of the virtual MTB limited participation for some clinicians (e.g., those located on the US West). However, this limitation was addressed by hosting biweekly, alternating afternoon journal club sessions with optional time to accommodate presentation of cases by presenters in different time zones, including international. The virtual MTB relied heavily on a strong leader to ensure discussions remained on track [2]. Notably, our study lacked a dedicated follow-up assessment. Therefore, similar to the study by Khalafallah et al. (2021) [15], it remains uncertain if the suggestions were actually followed and, moreover, if they resulted in positive clinical outcomes. While Lutterbach et al. (2005) [43] identified that the recommendations made by their interdisciplinary brain tumor board colleagues had a high potential to be implemented, Pillay et al. (2016) [44], noted little evidence indicating that MTBs improve clinical outcomes. Therefore, future prospective, longitudinal work is needed to investigate the impact of virtual neuro-oncology MTBs on measures such as enrollment to clinical trials and patient satisfaction and outcome. Importantly, our group is currently developing a prospective, structured, and standardized data collection system, in collaboration with the NIH Center for Cancer Research Office of Information Technology, to address many of the limitations noted in this present study. Our group also plans to expand the educational component of the MTB by creating a repository of presented cases. Lastly, the virtual MTB did not include experts in bioinformatics or molecular biology, who could have contributed to the identification of actionable molecular alterations. However, in CNS tumors the presence of actionable genetic alterations may not be sufficient to predict a therapeutic response as there are other important factors such as the blood brain barrier penetration of the drugs being considered and the presence of intrinsic or acquired resistance.

Conclusions

Our virtual multi-institutional MTB enabled expert review of challenging cases, regardless of geographic location of the patients. These novel remote meetings were particularly beneficial to formulate care plans for those with rare CNS tumors and AYAs, who face barriers to access specialized neuro-oncology providers. Our data also highlights the importance of advanced molecular testing in obtaining precise diagnoses and guiding treatment decisions, including discovering potentially actionable molecular targets with active clinical trial options. Ultimately, future work is needed to increase access to virtual MTBs and further refine administrative and logistical processes, with special attention to data protection and regulation of data access and sovereignty. Most importantly, virtual neuro-oncology MTBs open to external participants should remain an option post-pandemic to ensure equitable health care access.

Supplementary Information

Below is the link to the electronic supplementary material. Supplementary file1 (PDF 652 KB)

Supplementary file1 (DOCX 19.5 KB)

Author Contributions

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by James L. Rogers, Thomas Wall and Marta Penas-Prado. The first draft of the manuscript was written by James L. Rogers and all authors reviewed and commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding

Open access funding provided by the National Institutes of Health. This research was funded by the NCI Comprehensive Oncology Network for Evaluating Rare CNS Tumors (NCI-CONNECT), a program within the Rare Tumor Patient Engagement Network (RTPEN), an initiative supported by Cancer Moonshot℠ funds and managed at the National Institutes of Health, National Cancer Institute, Center for Cancer Research, Neuro-Oncology Branch.

Data Availability

The datasets generated during the current study are available from the corresponding author on reasonable request.

Declarations

Disclaimer

The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Uniformed Services University, Department of the Army, Department of Defense nor the US Government.

Conflicts of interest

Dr. Aboud has served on the advisory board for Servier. Dr. Cachia is a consultant for RedHill BioPharma Ltd, Guidepoint Global LLC, and Dedham Group and a paid speaker for the Massachusetts Neurological Society. Dr. Drappatz is a stock owner for Gilead, Pfizer, and GSK, receives royalties from Elsevier and Wolters Kluwer and receives research support from Servier and Novocure. Dr. Forsyth’s COI includes NIH/NCI (consultant), Pfizer (grant/research support), DOD (grant/research support), BMS (consultant), and Genentech (research support). Dr Lukas has served on advisory boards for Merck, AstraZeneca, Bayer, Cardinal Health, and Servier and serves on the speakers’ bureau for Merck and Novocure, receives research support (drug only) from BMS, and has received honoraria for medical editing from Medlink Neurology, Elsevier, EBSCO publishing, and Oxford University Press. Dr. Mandel is on the Medical advisory board for Servier and Bayer. Dr. Snyder received consulting fee from Monteris Medical Corporation and speaker fee from Blue Earth Diagnostics Limited. All other authors report no conflicts of interest.

James L. Rogers and Thomas Wall are coprimary authors.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Change history

9/4/2024

The original version of this article has been revised: The supplementary form has been added.
==== Refs
References 

1. Wheless SA McKinney KA Zanation AM A prospective study of the clinical impact of a multidisciplinary head and neck tumor board Otolaryngol Head Neck Surg 2010 143 650 654 10.1016/j.otohns.2010.07.020 20974334
Wheless SA, McKinney KA, Zanation AM (2010) A prospective study of the clinical impact of a multidisciplinary head and neck tumor board. Otolaryngol Head Neck Surg 143:650–654. 10.1016/j.otohns.2010.07.02020974334 10.1016/j.otohns.2010.07.020
2. Ruhstaller T Roe H Thurlimann B Nicoll JJ The multidisciplinary meeting: An indispensable aid to communication between different specialities Eur J Cancer 2006 42 2459 2462 10.1016/j.ejca.2006.03.034 16934974
Ruhstaller T, Roe H, Thurlimann B, Nicoll JJ (2006) The multidisciplinary meeting: An indispensable aid to communication between different specialities. Eur J Cancer 42:2459–2462. 10.1016/j.ejca.2006.03.03416934974 10.1016/j.ejca.2006.03.034
3. El Saghir NS Charara RN Kreidieh FY Eaton V Litvin K Farhat RA Khoury KE Breidy J Tamim H Eid TA Global Practice and Efficiency of Multidisciplinary Tumor Boards: Results of an American Society of Clinical Oncology International Survey J Glob Oncol 2015 1 57 64 10.1200/JGO.2015.000158 28804774
El Saghir NS, Charara RN, Kreidieh FY, Eaton V, Litvin K, Farhat RA, Khoury KE, Breidy J, Tamim H, Eid TA (2015) Global Practice and Efficiency of Multidisciplinary Tumor Boards: Results of an American Society of Clinical Oncology International Survey. J Glob Oncol 1:57–64. 10.1200/JGO.2015.00015828804774 10.1200/JGO.2015.000158
4. Snyder J Schultz L Walbert T The role of tumor board conferences in neuro-oncology: a nationwide provider survey J Neurooncol 2017 133 1 7 10.1007/s11060-017-2416-x 28421461
Snyder J, Schultz L, Walbert T (2017) The role of tumor board conferences in neuro-oncology: a nationwide provider survey. J Neurooncol 133:1–7. 10.1007/s11060-017-2416-x28421461 10.1007/s11060-017-2416-x
5. Jordan JT Mohile N Ney DE Nghiemphu PL Asher T Armstrong T Dunbar E Smith TR Sanders AE Bennett A Neuro-Oncology Quality Measurement Set Neurology 2018 90 14 652 658 10.1212/WNL.0000000000005251 29500290
Jordan JT, Mohile N, Ney DE, Nghiemphu PL, Asher T, Armstrong T, Dunbar E, Smith TR, Sanders AE, Bennett A (2018) Neuro-Oncology Quality Measurement Set. Neurology 90(14):652–65829500290 10.1212/WNL.0000000000005251
6. Parker BA Schwaederle M Scur MD Boles SG Helsten T Subramanian R Schwab RB Kurzrock R Breast Cancer Experience of the Molecular Tumor Board at the University of California, San Diego Moores Cancer Center J Oncol Pract 2015 11 442 449 10.1200/JOP.2015.004127 26243651
Parker BA, Schwaederle M, Scur MD, Boles SG, Helsten T, Subramanian R, Schwab RB, Kurzrock R (2015) Breast Cancer Experience of the Molecular Tumor Board at the University of California, San Diego Moores Cancer Center. J Oncol Pract 11:442–449. 10.1200/JOP.2015.00412726243651 10.1200/JOP.2015.004127
7. Louie BH Kato S Kim KH Lim HJ Lee S Okamura R Fanta PT Kurzrock R Precision medicine-based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience Mol Oncol 2022 16 2575 2584 10.1002/1878-0261.13202 35238467
Louie BH, Kato S, Kim KH, Lim HJ, Lee S, Okamura R, Fanta PT, Kurzrock R (2022) Precision medicine-based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience. Mol Oncol 16:2575–2584. 10.1002/1878-0261.1320235238467 10.1002/1878-0261.13202
8. Hsu PK Chien LI Huang CS Yeh YC Huang PI Chen MH Chen SY Yen CC Hsu HS Treatment Patterns and Outcomes in Patients with Esophageal Cancer: An Analysis of a Multidisciplinary Tumor Board Database Ann Surg Oncol 2022 29 572 585 10.1245/s10434-021-10568-z 34387767
Hsu PK, Chien LI, Huang CS, Yeh YC, Huang PI, Chen MH, Chen SY, Yen CC, Hsu HS (2022) Treatment Patterns and Outcomes in Patients with Esophageal Cancer: An Analysis of a Multidisciplinary Tumor Board Database. Ann Surg Oncol 29:572–585. 10.1245/s10434-021-10568-z34387767 10.1245/s10434-021-10568-z
9. Bartoletti M Bergamini A Giannone G Nero C Musacchio L Farolfi A Passarelli A Kuhn E Castaldo D Lombardo V Di Palma T Lorusso D Puglisi F De Giorgi U Valabrega G Schettino C Scambia G Capoluongo E Pignata S A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group Int J Gynecol Cancer 2022 10.1136/ijgc-2022-003425.10.1136/ijgc-2022-003425 35318277
Bartoletti M, Bergamini A, Giannone G, Nero C, Musacchio L, Farolfi A, Passarelli A, Kuhn E, Castaldo D, Lombardo V, Di Palma T, Lorusso D, Puglisi F, De Giorgi U, Valabrega G, Schettino C, Scambia G, Capoluongo E, Pignata S (2022) A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group. Int J Gynecol Cancer. 10.1136/ijgc-2022-003425.10.1136/ijgc-2022-00342535318277 10.1136/ijgc-2022-003425.10.1136/ijgc-2022-003425
10. Ronden MI Bahce I Hashemi SMS Dickhoff C de Haan PF Becker A Spoelstra FOB Dahele MR Ali R Tiemessen MA Tarasevych S Maassen van den Brink K Haasbeek CJA Daniels JMA van Laren M Verbakel W Senan S Factors influencing multi-disciplinary tumor board recommendations in stage III non-small cell lung cancer Lung Cancer 2021 152 149 156 10.1016/j.lungcan.2020.12.019 33418430
Ronden MI, Bahce I, Hashemi SMS, Dickhoff C, de Haan PF, Becker A, Spoelstra FOB, Dahele MR, Ali R, Tiemessen MA, Tarasevych S, Maassen van den Brink K, Haasbeek CJA, Daniels JMA, van Laren M, Verbakel W, Senan S (2021) Factors influencing multi-disciplinary tumor board recommendations in stage III non-small cell lung cancer. Lung Cancer 152:149–156. 10.1016/j.lungcan.2020.12.01933418430 10.1016/j.lungcan.2020.12.019
11. Quero G Salvatore L Fiorillo C Bagala C Menghi R Maria B Cina C Laterza V Di Stefano B Maratta MG Ribelli M Galiandro F Mattiucci GC Brizi MG Genco E D'Aversa F Zileri L Attili F Larghi A Perri V Inzani F Gasbarrini A Valentini V Costamagna G Manfredi R Tortora G Alfieri S The impact of the multidisciplinary tumor board (MDTB) on the management of pancreatic diseases in a tertiary referral center ESMO Open 2021 6 100010 10.1016/j.esmoop.2020.100010 33399076
Quero G, Salvatore L, Fiorillo C, Bagala C, Menghi R, Maria B, Cina C, Laterza V, Di Stefano B, Maratta MG, Ribelli M, Galiandro F, Mattiucci GC, Brizi MG, Genco E, D’Aversa F, Zileri L, Attili F, Larghi A, Perri V, Inzani F, Gasbarrini A, Valentini V, Costamagna G, Manfredi R, Tortora G, Alfieri S (2021) The impact of the multidisciplinary tumor board (MDTB) on the management of pancreatic diseases in a tertiary referral center. ESMO Open 6:100010. 10.1016/j.esmoop.2020.10001033399076 10.1016/j.esmoop.2020.100010
12. Jalil R Soukup T Akhter W Sevdalis N Green JSA Quality of leadership in multidisciplinary cancer tumor boards: development and evaluation of a leadership assessment instrument (ATLAS) World J Urol 2018 36 1031 1038 10.1007/s00345-018-2255-1 29502300
Jalil R, Soukup T, Akhter W, Sevdalis N, Green JSA (2018) Quality of leadership in multidisciplinary cancer tumor boards: development and evaluation of a leadership assessment instrument (ATLAS). World J Urol 36:1031–1038. 10.1007/s00345-018-2255-129502300 10.1007/s00345-018-2255-1
13. Specchia ML Frisicale EM Carini E Di Pilla A Cappa D Barbara A Ricciardi W Damiani G The impact of tumor board on cancer care: evidence from an umbrella review BMC Health Serv Res 2020 20 73 10.1186/s12913-020-4930-3 32005232
Specchia ML, Frisicale EM, Carini E, Di Pilla A, Cappa D, Barbara A, Ricciardi W, Damiani G (2020) The impact of tumor board on cancer care: evidence from an umbrella review. BMC Health Serv Res 20:73. 10.1186/s12913-020-4930-332005232 10.1186/s12913-020-4930-3
14. Freytag M Herrlinger U Hauser S Bauernfeind FG Gonzalez-Carmona MA Landsberg J Buermann J Vatter H Holderried T Send T Schumacher M Koscielny A Feldmann G Heine M Skowasch D Schafer N Funke B Neumann M Schmidt-Wolf IGH Higher number of multidisciplinary tumor board meetings per case leads to improved clinical outcome BMC Cancer 2020 20 355 10.1186/s12885-020-06809-1 32345242
Freytag M, Herrlinger U, Hauser S, Bauernfeind FG, Gonzalez-Carmona MA, Landsberg J, Buermann J, Vatter H, Holderried T, Send T, Schumacher M, Koscielny A, Feldmann G, Heine M, Skowasch D, Schafer N, Funke B, Neumann M, Schmidt-Wolf IGH (2020) Higher number of multidisciplinary tumor board meetings per case leads to improved clinical outcome. BMC Cancer 20:355. 10.1186/s12885-020-06809-132345242 10.1186/s12885-020-06809-1
15. Khalafallah AM Jimenez AE Romo CG Kamson DO Kleinberg L Weingart J Brem H Grossman SA Mukherjee D Quantifying the utility of a multidisciplinary neuro-oncology tumor board J Neurosurg 2020 135 87 92 10.3171/2020.5.JNS201299 32947258
Khalafallah AM, Jimenez AE, Romo CG, Kamson DO, Kleinberg L, Weingart J, Brem H, Grossman SA, Mukherjee D (2020) Quantifying the utility of a multidisciplinary neuro-oncology tumor board. J Neurosurg 135:87–92. 10.3171/2020.5.JNS20129932947258 10.3171/2020.5.JNS201299
16. Schafer N Bumes E Eberle F Fox V Gessler F Giordano FA Konczalla J Onken J Ottenhausen M Scherer M Schneider M Vatter H Herrlinger U Schuss P Implementation, relevance, and virtual adaptation of neuro-oncological tumor boards during the COVID-19 pandemic: a nationwide provider survey J Neurooncol 2021 153 479 485 10.1007/s11060-021-03784-w 34115248
Schafer N, Bumes E, Eberle F, Fox V, Gessler F, Giordano FA, Konczalla J, Onken J, Ottenhausen M, Scherer M, Schneider M, Vatter H, Herrlinger U, Schuss P (2021) Implementation, relevance, and virtual adaptation of neuro-oncological tumor boards during the COVID-19 pandemic: a nationwide provider survey. J Neurooncol 153:479–485. 10.1007/s11060-021-03784-w34115248 10.1007/s11060-021-03784-w
17. Gaudino S Giordano C Magnani F Cottonaro S Infante A Sabatino G La Rocca G Della Pepa GM D'Alessandris QG Pallini R Olivi A Balducci M Chiesa S Gessi M Guadalupi P Russo R Schiarelli C Ausili Cefaro L Di Lella GM Colosimo C Neuro-Oncology Multidisciplinary Tumor Board: The Point of View of the Neuroradiologist J Pers Med 2022 12 135 10.3390/jpm12020135 35207625
Gaudino S, Giordano C, Magnani F, Cottonaro S, Infante A, Sabatino G, La Rocca G, Della Pepa GM, D’Alessandris QG, Pallini R, Olivi A, Balducci M, Chiesa S, Gessi M, Guadalupi P, Russo R, Schiarelli C, Ausili Cefaro L, Di Lella GM, Colosimo C (2022) Neuro-Oncology Multidisciplinary Tumor Board: The Point of View of the Neuroradiologist. J Pers Med 12:135. 10.3390/jpm1202013535207625 10.3390/jpm12020135
18. Ivanovic V Assadsangabi R Hacein-Bey L Raslan O Bobinski M Latchaw R Qi L Neuroradiology diagnostic errors at a tertiary academic centre: effect of participation in tumour boards and physician experience Clin Radiol 2022 77 607 612 10.1016/j.crad.2022.04.006 35589432
Ivanovic V, Assadsangabi R, Hacein-Bey L, Raslan O, Bobinski M, Latchaw R, Qi L (2022) Neuroradiology diagnostic errors at a tertiary academic centre: effect of participation in tumour boards and physician experience. Clin Radiol 77:607–612. 10.1016/j.crad.2022.04.00635589432 10.1016/j.crad.2022.04.006
19. Ostrom QT Patil N Cioffi G Waite K Kruchko C Barnholtz-Sloan JS CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017 Neuro Oncol 2020 22 iv1 iv96 10.1093/neuonc/noaa200 33123732
Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS (2020) CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017. Neuro Oncol 22:iv1–iv96. 10.1093/neuonc/noaa20033123732 10.1093/neuonc/noaa200
20. Truitt G Gittleman H Leece R Ostrom QT Kruchko C Armstrong TS Gilbert MR Barnholtz-Sloan JS Partnership for defining the impact of 12 selected rare CNS tumors: a report from the CBTRUS and the NCI-CONNECT J Neurooncol 2019 144 53 63 10.1007/s11060-019-03215-x 31209773
Truitt G, Gittleman H, Leece R, Ostrom QT, Kruchko C, Armstrong TS, Gilbert MR, Barnholtz-Sloan JS (2019) Partnership for defining the impact of 12 selected rare CNS tumors: a report from the CBTRUS and the NCI-CONNECT. J Neurooncol 144:53–63. 10.1007/s11060-019-03215-x31209773 10.1007/s11060-019-03215-x
21 Mansouri A Zadeh G NCI-CONNECT rare CNS tumor initiative: current progress and anticipated future impact Neurooncol Adv 2020 2 vdaa022 10.1093/noajnl/vdaa022 32642683
Mansouri A, Zadeh G (2020) NCI-CONNECT rare CNS tumor initiative: current progress and anticipated future impact. Neurooncol Adv 2:vdaa022. 10.1093/noajnl/vdaa02232642683 10.1093/noajnl/vdaa022
22. Penas-Prado M Armstrong TS Gilbert MR Proposed Additions to the NCCN Guidelines for Adult Medulloblastoma J Natl Compr Canc Netw 2020 18 1579 1584 10.6004/jnccn.2020.7650 33152706
Penas-Prado M, Armstrong TS, Gilbert MR (2020) Proposed Additions to the NCCN Guidelines for Adult Medulloblastoma. J Natl Compr Canc Netw 18:1579–1584. 10.6004/jnccn.2020.765033152706 10.6004/jnccn.2020.7650
23. Penas-Prado M Wu J Cahill DP Brat DJ Costello JF Kluetz PG Cairncross JG van den Bent M Verhaak RGW Aboud O Burger P Chang SM Cordova C Huang RY Rowe LS Taphoorn MJB Gilbert MR Armstrong TS Workshop N-CO Proceedings of the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) Oligodendroglioma Workshop Neurooncol Adv 2020 2 048 10.1093/noajnl/vdz048
Penas-Prado M, Wu J, Cahill DP, Brat DJ, Costello JF, Kluetz PG, Cairncross JG, van den Bent M, Verhaak RGW, Aboud O, Burger P, Chang SM, Cordova C, Huang RY, Rowe LS, Taphoorn MJB, Gilbert MR, Armstrong TS, Workshop N-CO (2020) Proceedings of the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) Oligodendroglioma Workshop. Neurooncol Adv 2:048. 10.1093/noajnl/vdz04810.1093/noajnl/vdz048
24. Theeler BJ Dalal Y Monje M Shilatifard A Suva ML Aboud O Camphausen K Cordova C Finch E Heiss JD Packer RJ Romo CG Aldape K Penas-Prado M Armstrong T Gilbert MR NCI-CONNECT: Comprehensive Oncology Network Evaluating Rare CNS Tumors-Histone Mutated Midline Glioma Workshop Proceedings Neurooncol Adv 2020 2 vdaa007 10.1093/noajnl/vdaa007 32642676
Theeler BJ, Dalal Y, Monje M, Shilatifard A, Suva ML, Aboud O, Camphausen K, Cordova C, Finch E, Heiss JD, Packer RJ, Romo CG, Aldape K, Penas-Prado M, Armstrong T, Gilbert MR (2020) NCI-CONNECT: Comprehensive Oncology Network Evaluating Rare CNS Tumors-Histone Mutated Midline Glioma Workshop Proceedings. Neurooncol Adv 2:vdaa007. 10.1093/noajnl/vdaa00732642676 10.1093/noajnl/vdaa007
25. Leeper HE Tonorezos E Mayer D Bakitas M Chang S Cooley ME Hervey-Jumper S Miaskowski C Sherwood P Tsien C Wallgren K Willmarth N Arons D Acquaye A King AL Penas-Prado M Vera E Gilbert MR Armstrong TS Workshop N-CSCiN-O, Proceedings of the Survivorship Care in Neuro-Oncology Workshop sponsored by the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) Neurooncol Adv 2022 4 vdac029 10.1093/noajnl/vdac029 35542753
Leeper HE, Tonorezos E, Mayer D, Bakitas M, Chang S, Cooley ME, Hervey-Jumper S, Miaskowski C, Sherwood P, Tsien C, Wallgren K, Willmarth N, Arons D, Acquaye A, King AL, Penas-Prado M, Vera E, Gilbert MR, Armstrong TS, Workshop N-CSCiN-O, (2022) Proceedings of the Survivorship Care in Neuro-Oncology Workshop sponsored by the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT). Neurooncol Adv 4:vdac029. 10.1093/noajnl/vdac02935542753 10.1093/noajnl/vdac029
26. Penas-Prado M Rare central nervous system tumors: the path to progress Neuro Oncol 2021 23 S1 S3 10.1093/neuonc/noab144 34725695
Penas-Prado M (2021) Rare central nervous system tumors: the path to progress. Neuro Oncol 23:S1–S3. 10.1093/neuonc/noab14434725695 10.1093/neuonc/noab144
27. Penas-Prado M Theeler BJ Cordeiro B Dunkel IJ Hau P Mahajan A Robinson GW Willmarth N Aboud O Aldape K Butman JA Gajjar A Kelly W Rao G Raygada M Siegel C Romo CG Armstrong TS Gilbert MR Workshop N-CAM Proceedings of the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) Adult Medulloblastoma Workshop Neurooncol Adv 2020 2 vdaa097 10.1093/noajnl/vdaa097 33005896
Penas-Prado M, Theeler BJ, Cordeiro B, Dunkel IJ, Hau P, Mahajan A, Robinson GW, Willmarth N, Aboud O, Aldape K, Butman JA, Gajjar A, Kelly W, Rao G, Raygada M, Siegel C, Romo CG, Armstrong TS, Gilbert MR, Workshop N-CAM (2020) Proceedings of the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) Adult Medulloblastoma Workshop. Neurooncol Adv 2:vdaa097. 10.1093/noajnl/vdaa09733005896 10.1093/noajnl/vdaa097
28. Wasilewski A Mohile N Tele-neuro-oncology: Current Practices and Future Directions Curr Oncol Rep 2022 24 99 103 10.1007/s11912-021-01176-x 35059995
Wasilewski A, Mohile N (2022) Tele-neuro-oncology: Current Practices and Future Directions. Curr Oncol Rep 24:99–103. 10.1007/s11912-021-01176-x35059995 10.1007/s11912-021-01176-x
29. Capper D Jones DTW Sill M Hovestadt V Schrimpf D Sturm D Koelsche C Sahm F Chavez L Reuss DE Kratz A Wefers AK Huang K Pajtler KW Schweizer L Stichel D Olar A Engel NW Lindenberg K Harter PN Braczynski AK Plate KH Dohmen H Garvalov BK Coras R Holsken A Hewer E Bewerunge-Hudler M Schick M Fischer R Beschorner R Schittenhelm J Staszewski O Wani K Varlet P Pages M Temming P Lohmann D Selt F Witt H Milde T Witt O Aronica E Giangaspero F Rushing E Scheurlen W Geisenberger C Rodriguez FJ Becker A Preusser M Haberler C Bjerkvig R Cryan J Farrell M Deckert M Hench J Frank S Serrano J Kannan K Tsirigos A Bruck W Hofer S Brehmer S Seiz-Rosenhagen M Hanggi D Hans V Rozsnoki S Hansford JR Kohlhof P Kristensen BW Lechner M Lopes B Mawrin C Ketter R Kulozik A Khatib Z Heppner F Koch A Jouvet A Keohane C Muhleisen H Mueller W Pohl U Prinz M Benner A Zapatka M Gottardo NG Driever PH Kramm CM Muller HL Rutkowski S von Hoff K Fruhwald MC Gnekow A Fleischhack G Tippelt S Calaminus G Monoranu CM Perry A Jones C Jacques TS Radlwimmer B Gessi M Pietsch T Schramm J Schackert G Westphal M Reifenberger G Wesseling P Weller M Collins VP Blumcke I Bendszus M Debus J Huang A Jabado N Northcott PA Paulus W Gajjar A Robinson GW Taylor MD Jaunmuktane Z Ryzhova M Platten M Unterberg A Wick W Karajannis MA Mittelbronn M Acker T Hartmann C Aldape K Schuller U Buslei R Lichter P Kool M Herold-Mende C Ellison DW Hasselblatt M Snuderl M Brandner S Korshunov A von Deimling A Pfister SM DNA methylation-based classification of central nervous system tumours Nature 2018 555 469 474 10.1038/nature26000 29539639
Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, Koelsche C, Sahm F, Chavez L, Reuss DE, Kratz A, Wefers AK, Huang K, Pajtler KW, Schweizer L, Stichel D, Olar A, Engel NW, Lindenberg K, Harter PN, Braczynski AK, Plate KH, Dohmen H, Garvalov BK, Coras R, Holsken A, Hewer E, Bewerunge-Hudler M, Schick M, Fischer R, Beschorner R, Schittenhelm J, Staszewski O, Wani K, Varlet P, Pages M, Temming P, Lohmann D, Selt F, Witt H, Milde T, Witt O, Aronica E, Giangaspero F, Rushing E, Scheurlen W, Geisenberger C, Rodriguez FJ, Becker A, Preusser M, Haberler C, Bjerkvig R, Cryan J, Farrell M, Deckert M, Hench J, Frank S, Serrano J, Kannan K, Tsirigos A, Bruck W, Hofer S, Brehmer S, Seiz-Rosenhagen M, Hanggi D, Hans V, Rozsnoki S, Hansford JR, Kohlhof P, Kristensen BW, Lechner M, Lopes B, Mawrin C, Ketter R, Kulozik A, Khatib Z, Heppner F, Koch A, Jouvet A, Keohane C, Muhleisen H, Mueller W, Pohl U, Prinz M, Benner A, Zapatka M, Gottardo NG, Driever PH, Kramm CM, Muller HL, Rutkowski S, von Hoff K, Fruhwald MC, Gnekow A, Fleischhack G, Tippelt S, Calaminus G, Monoranu CM, Perry A, Jones C, Jacques TS, Radlwimmer B, Gessi M, Pietsch T, Schramm J, Schackert G, Westphal M, Reifenberger G, Wesseling P, Weller M, Collins VP, Blumcke I, Bendszus M, Debus J, Huang A, Jabado N, Northcott PA, Paulus W, Gajjar A, Robinson GW, Taylor MD, Jaunmuktane Z, Ryzhova M, Platten M, Unterberg A, Wick W, Karajannis MA, Mittelbronn M, Acker T, Hartmann C, Aldape K, Schuller U, Buslei R, Lichter P, Kool M, Herold-Mende C, Ellison DW, Hasselblatt M, Snuderl M, Brandner S, Korshunov A, von Deimling A, Pfister SM (2018) DNA methylation-based classification of central nervous system tumours. Nature 555:469–474. 10.1038/nature2600029539639 10.1038/nature26000
30. Fennell ML Das IP Clauser S Petrelli N Salner A The organization of multidisciplinary care teams: modeling internal and external influences on cancer care quality J Natl Cancer Inst Monogr 2010 2010 72 80 10.1093/jncimonographs/lgq010 20386055
Fennell ML, Das IP, Clauser S, Petrelli N, Salner A (2010) The organization of multidisciplinary care teams: modeling internal and external influences on cancer care quality. J Natl Cancer Inst Monogr 2010:72–80. 10.1093/jncimonographs/lgq01020386055 10.1093/jncimonographs/lgq010
31. Lee EQ Chukwueke UN Hervey-Jumper SL de Groot JF Leone JP Armstrong TS Chang SM Arons D Oliver K Verble K Musella A Willmarth N Alexander BM Bates A Doherty L Galanis E Gaffey S Halkin T Friday BE Fouladi M Lin NU Macdonald D Mehta MP Penas-Prado M Vogelbaum MA Sahebjam S Sandak D van den Bent M Weller M Reardon DA Wen PY Barriers to accrual and enrollment in brain tumor trials Neuro Oncol 2019 21 1100 1117 10.1093/neuonc/noz104 31175826
Lee EQ, Chukwueke UN, Hervey-Jumper SL, de Groot JF, Leone JP, Armstrong TS, Chang SM, Arons D, Oliver K, Verble K, Musella A, Willmarth N, Alexander BM, Bates A, Doherty L, Galanis E, Gaffey S, Halkin T, Friday BE, Fouladi M, Lin NU, Macdonald D, Mehta MP, Penas-Prado M, Vogelbaum MA, Sahebjam S, Sandak D, van den Bent M, Weller M, Reardon DA, Wen PY (2019) Barriers to accrual and enrollment in brain tumor trials. Neuro Oncol 21:1100–1117. 10.1093/neuonc/noz10431175826 10.1093/neuonc/noz104
32. Rogers JL Acquaye A Vera E Bates A Wen PY Armstrong TS Provider-reported challenges and barriers to referring patients to neuro-oncology clinical trials: a report from the Society for Neuro-Oncology member survey Neurooncol Pract 2020 7 38 51 10.1093/nop/npz038 32257283
Rogers JL, Acquaye A, Vera E, Bates A, Wen PY, Armstrong TS (2020) Provider-reported challenges and barriers to referring patients to neuro-oncology clinical trials: a report from the Society for Neuro-Oncology member survey. Neurooncol Pract 7:38–51. 10.1093/nop/npz03832257283 10.1093/nop/npz038
33. Pratt D Sahm F Aldape K DNA methylation profiling as a model for discovery and precision diagnostics in neuro-oncology Neuro Oncol 2021 23 S16 S29 10.1093/neuonc/noab143 34725697
Pratt D, Sahm F, Aldape K (2021) DNA methylation profiling as a model for discovery and precision diagnostics in neuro-oncology. Neuro Oncol 23:S16–S29. 10.1093/neuonc/noab14334725697 10.1093/neuonc/noab143
34. Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C, Paulus W, Perry A, Reifenberger G, Figarella-Branger D (2017) Announcing cIMPACT-NOW: the consortium to inform molecular and practical approaches to CNS tumor taxonomy. Acta Neuropathol 133(1):1–3. 10.1007/s00401-016-1646-x
35. Louis DN Perry A Wesseling P Brat DJ Cree IA Figarella-Branger D Hawkins C Ng HK Pfister SM Reifenberger G Soffietti R von Deimling A Ellison DW The 2021 WHO Classification of Tumors of the Central Nervous System: a summary Neuro Oncol 2021 23 1231 1251 10.1093/neuonc/noab106 34185076
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23:1231–1251. 10.1093/neuonc/noab10634185076 10.1093/neuonc/noab106
36. Ji MS Eldred BSC Liu R Pianka ST Molaie D Kevan B Pan S Lai TJ Nguyen NT Chow FE Yong WH Cox CD Reeh DN Li T Liau LM Nghiemphu PL Cloughesy TF Li G Lai A Targeted next-generation sequencing of 565 neuro-oncology patients at UCLA: A single-institution experience Neurooncol Adv 2020 2 vdaa009 10.1093/noajnl/vdaa009 32118206
Ji MS, Eldred BSC, Liu R, Pianka ST, Molaie D, Kevan B, Pan S, Lai TJ, Nguyen NT, Chow FE, Yong WH, Cox CD, Reeh DN, Li T, Liau LM, Nghiemphu PL, Cloughesy TF, Li G, Lai A (2020) Targeted next-generation sequencing of 565 neuro-oncology patients at UCLA: A single-institution experience. Neurooncol Adv 2:vdaa009. 10.1093/noajnl/vdaa00932118206 10.1093/noajnl/vdaa009
37. Capper D Stichel D Sahm F Jones DTW Schrimpf D Sill M Schmid S Hovestadt V Reuss DE Koelsche C Reinhardt A Wefers AK Huang K Sievers P Ebrahimi A Scholer A Teichmann D Koch A Hanggi D Unterberg A Platten M Wick W Witt O Milde T Korshunov A Pfister SM von Deimling A Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience Acta Neuropathol 2018 136 181 210 10.1007/s00401-018-1879-y 29967940
Capper D, Stichel D, Sahm F, Jones DTW, Schrimpf D, Sill M, Schmid S, Hovestadt V, Reuss DE, Koelsche C, Reinhardt A, Wefers AK, Huang K, Sievers P, Ebrahimi A, Scholer A, Teichmann D, Koch A, Hanggi D, Unterberg A, Platten M, Wick W, Witt O, Milde T, Korshunov A, Pfister SM, von Deimling A (2018) Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. Acta Neuropathol 136:181–210. 10.1007/s00401-018-1879-y29967940 10.1007/s00401-018-1879-y
38. Karimi S Zuccato JA Mamatjan Y Mansouri S Suppiah S Nassiri F Diamandis P Munoz DG Aldape KD Zadeh G The central nervous system tumor methylation classifier changes neuro-oncology practice for challenging brain tumor diagnoses and directly impacts patient care Clin Epigenetics 2019 11 185 10.1186/s13148-019-0766-2 31806041
Karimi S, Zuccato JA, Mamatjan Y, Mansouri S, Suppiah S, Nassiri F, Diamandis P, Munoz DG, Aldape KD, Zadeh G (2019) The central nervous system tumor methylation classifier changes neuro-oncology practice for challenging brain tumor diagnoses and directly impacts patient care. Clin Epigenetics 11:185. 10.1186/s13148-019-0766-231806041 10.1186/s13148-019-0766-2
39. Wu Z Abdullaev Z Pratt D Chung HJ Skarshaug S Zgonc V Perry C Pack S Saidkhodjaeva L Nagaraj S Tyagi M Gangalapudi V Valdez K Turakulov R Xi L Raffeld M Papanicolau-Sengos A O'Donnell K Newford M Gilbert MR Sahm F Suwala AK von Deimling A Mamatjan Y Karimi S Nassiri F Zadeh G Ruppin E Quezado M Aldape K Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics Neuro Oncol 2022 24 571 581 10.1093/neuonc/noab227 34555175
Wu Z, Abdullaev Z, Pratt D, Chung HJ, Skarshaug S, Zgonc V, Perry C, Pack S, Saidkhodjaeva L, Nagaraj S, Tyagi M, Gangalapudi V, Valdez K, Turakulov R, Xi L, Raffeld M, Papanicolau-Sengos A, O’Donnell K, Newford M, Gilbert MR, Sahm F, Suwala AK, von Deimling A, Mamatjan Y, Karimi S, Nassiri F, Zadeh G, Ruppin E, Quezado M, Aldape K (2022) Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics. Neuro Oncol 24:571–581. 10.1093/neuonc/noab22734555175 10.1093/neuonc/noab227
40. Aboud O Shah R Vera E Burton E Theeler B Wu J Boris L Quezado M Reyes J Wall K Challenges of imaging interpretation to predict oligodendroglioma grade: a report from the Neuro-Oncology Branch CNS oncology 2022 11 CNS83 10.2217/cns-2021-0005 35142534
Aboud O, Shah R, Vera E, Burton E, Theeler B, Wu J, Boris L, Quezado M, Reyes J, Wall K (2022) Challenges of imaging interpretation to predict oligodendroglioma grade: a report from the Neuro-Oncology Branch. CNS oncology 11:CNS8335142534 10.2217/cns-2021-0005
41. Armstrong T Gilbert M P18. 01 The Neuro-Oncology Branch Patient Outcomes Program (POP) Neuro-Oncology 2017 19 iii120 10.1093/neuonc/nox036.465
Armstrong T, Gilbert M (2017) P18. 01 The Neuro-Oncology Branch Patient Outcomes Program (POP). Neuro-Oncology 19:iii12010.1093/neuonc/nox036.465
42. Lamb BW Sevdalis N Arora S Pinto A Vincent C Green JS Teamwork and team decision-making at multidisciplinary cancer conferences: barriers, facilitators, and opportunities for improvement World J Surg 2011 35 1970 1976 10.1007/s00268-011-1152-1 21604049
Lamb BW, Sevdalis N, Arora S, Pinto A, Vincent C, Green JS (2011) Teamwork and team decision-making at multidisciplinary cancer conferences: barriers, facilitators, and opportunities for improvement. World J Surg 35:1970–1976. 10.1007/s00268-011-1152-121604049 10.1007/s00268-011-1152-1
43. Lutterbach J Pagenstecher A Spreer J Hetzel A Velthoven V Nikkhah G Frommhold H Volk B Schumacher M Lucking C Zentner J Ostertag C The brain tumor board: lessons to be learned from an interdisciplinary conference Onkologie 2005 28 22 26 10.1159/000082124 15616378
Lutterbach J, Pagenstecher A, Spreer J, Hetzel A, Velthoven V, Nikkhah G, Frommhold H, Volk B, Schumacher M, Lucking C, Zentner J, Ostertag C (2005) The brain tumor board: lessons to be learned from an interdisciplinary conference. Onkologie 28:22–26. 10.1159/00008212415616378 10.1159/000082124
44. Pillay B Wootten AC Crowe H Corcoran N Tran B Bowden P Crowe J Costello AJ The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature Cancer Treat Rev 2016 42 56 72 10.1016/j.ctrv.2015.11.007 26643552
Pillay B, Wootten AC, Crowe H, Corcoran N, Tran B, Bowden P, Crowe J, Costello AJ (2016) The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature. Cancer Treat Rev 42:56–72. 10.1016/j.ctrv.2015.11.00726643552 10.1016/j.ctrv.2015.11.007
